Michael Crowley - Feb 27, 2024 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO BIOB)

Role: EVP, GBL Commercial Operations
Signature: /s/ Michael Crowley
Stock symbol: BIO BIOB
Transactions as of: Feb 27, 2024
Transactions value $: -$360,060
Form type: 4
Date filed: 2/28/2024, 06:38 PM
Previous filing: Nov 28, 2023
Next filing: Mar 12, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BIO BIOB	Bio-Rad A Common Stock	Options Exercise	$648K	+3K	+43.22%	$215.98	9.94K	Feb 27, 2024	Direct
transaction	BIO BIOB	Bio-Rad A Common Stock	Sale	-$1.01M	-3K	-30.18%	$336.00	6.94K	Feb 27, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BIO BIOB	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-3K	-100%	$0.00^*	0	Feb 27, 2024	Bio-Rad A Common Stock	3K	$215.98	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $335.53 to $336.20, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 5, 2018, which was the first anniversary of the date on which the option was granted.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $335.53 to $336.20, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 5, 2018, which was the first anniversary of the date on which the option was granted.